Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Purpose

This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.

 

In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months. 

Could this study be right for you?

Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)

Must have not had a CT scan in the past 12 months

HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study

Able to understand and provide informed consent

Possess a smart phone that can browse the web

Not receiving any other smoking cessation interventions currently or within the prior 30 days

Female volunteers cannot be pregnant, lactating, or breast-feeding

Age Range

45 - 80 years

Official Title Creating a Mobile Health Program for Teens with Congenital Heart Disease

Purpose

The purpose of this study is to learn more about what teens with congenital heart disease want in a program that helps them learn more about living with congenital heart disease, dealing with stress, and staying away from e-cigarettes. The information from your participation may help us understand how we can improve the program and make it more interesting and appealing for teens.

Could this study be right for you?

• Have a diagnosis of a structural congenital heart defect
• No cognitive impairments limiting ability to complete study interview/questionnaires
• Proficient in English
• Have access to a device that can connect to the internet
• Not leaving the country at any point during study participation

**This study is invite only. Study staff will contact you if you are invited to participate.**

Age Range

12 - 18 years

Official Title Effects of Acute and Chronic Ketone Ester Consumption on Exercise Tolerance and Cardiac Function in Subjects with Diabetes

Purpose

This placebo-controlled study is being done to evaluate the effects of a ketone ester drink on exercise performance and heart health in a group of subjects diagnosed with type 2 diabetes.

Could this study be right for you?

There are additional exclusion criteria, study staff will screen fully before enrollment.

Age Range

18 - 80 years

Official Title Radiotracer Imaging of Lower Extremity Skeletal Muscle Perfusion in Patients with Peripheral Arterial Disease

Purpose

The purpose of this study is to look at a new method to evaluate blood flow to the calves and feet. 

Peripheral Artery Disease (PAD) patient outcomes will be evaluated for up to 12 months after their revascularization procedure to assess how early changes in SPECT-derived foot perfusion relate to rates of diabetic wound healing and limb salvage. Outcomes will be specifically evaluated at 3, 6, 9, and 12 months after revascularization at the time of their follow-up clinic visits to the OSU Comprehensive Wound Center at OSU Hospital East. Primary outcomes of interest will be 1) changes in wound size and healing, 2) minor or major amputations of the lower extremity, and 3) any subsequent interventional procedures, such as balloon angioplasty, stenting, or surgical bypass.

 

Could this study be right for you?

Heathly Volunteers with out previous cardiovascular disease

Or 

PAD

Age Range

18 years and up

Official Title IMPROVE-AD Trial: IMPRoving Outcomes in Vascular DisEase – Aortic Dissection

Purpose

The goal of this study is to figure out the best way to treat type aortic dissection. An aortic dissection is a tear in the wall of the aorta. The aorta is a big blood vessel that carries blood from your heart to the rest of your body. Individuals with this problem usually get medicine or a special repair procedure. This procedure is called thoracic endovascular aortic repair (TEVAR). TEVAR is a procedure where a metal tube (called a stent), is inserted in the damaged part of the aorta. The study is being done to figure out which treatment works better. The results of the study may help to prevent future problems with the aorta or other health issues. 

 

Could this study be right for you?

Inclusion:

• Age > 21 years
• Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)
• Acuity: within 48 hours – 6 weeks of index admission

Exclusion criteria:

• Ongoing systemic infection
• Pregnant or planning to become pregnant in the next 3 months
• Life expectancy related to non-aortic conditions < 2 years
• Prior surgery for aortic dissection

Age Range

21 years and up

Official Title AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

Purpose

The purpose of this research is to determine if the IMPEDE-FX RapidFill System is safe and helps to shrink abdominal aortic aneurysm (AAA - a bulge or swelling due to weakening of the walls of the aorta, which is the main blood vessel that carries blood from your heart to other parts of your body) sacs after an endovascular stent graft (a fabric tube supported by metal wire stents that reinforces a weakened aorta) has been placed. The IMPEDE-FX RapidFill System used in this study is classified as investigational, which means it has not been approved by the Food and Drug Administration (FDA).

Could this study be right for you?

Inclusion:

• A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm ≥5.5 cm in diameter in men and ≥ 5.0 cm in women 
• Thrombus burden (percentage of the AAA sac occupied by thrombus) <50%, based on pre-procedure CTA
• Maximum Lumen diameter within the AAA sac of ≥40mm
• The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is ≤200

Exclusion:

• An inability to provide informed consent
• Enrolled in another clinical study that could interfere with the outcomes being studied in this trial
• Unable or unwilling to comply with study follow-up requirements

Inclusion and Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

18 years and up

Official Title The mom and infant outcomes (MOMI) study: A trial of perinatal outpatient delivery systems

Purpose

​To improve our ability to provide the best possible care to every mom and infant, we are testing two different models of primary care during the first year after childbirth.

Could this study be right for you?

• You may qualify if you’re currently pregnant – AND – you’ve ever had high blood pressure, diabetes, depression, or anxiety, including during pregnancy.

If you participate, you’ll be randomly assigned to an Ohio State location that delivers one of two models of care. Providers at all locations can help you manage your health, but the models differ in several ways.

• You’ll complete three study visits with surveys, several measurements, and blood and hair sampling. We’ll collect cord blood and review medical records.

Official Title Patterns Of Survivors’ Recovery Trajectories in the ICECAP trial 􀂥POST-ICECAP􀂦

Purpose

The purpose of this study is to describe the physical, neuropsychological outcomes of adults who have experienced an outside of hospital cardiac arrest; and examine any associations between those outcomes and any clinical and/or rehabilitative interventions and/or social determinants of health.

Could this study be right for you?

• Experienced a coma after resuscitation from a cardiac arrest
• Received targeted/controlled body temperature management
• Survived to at least 1 month after experiencing a outside of hospital cardiac arrest

Age Range

18 years and up

Official Title A prospective randomized unblinded study of ketogenetic versus mixed diet on exercise tolerance in subjects with the metabolic phenotype of heart failure with preserved ejection fraction

Purpose

The purpose of this study is to compare the effects of a well-formulated ketogenic diet with a low-fat diet on exercise tolerance in patients with heart failure and diabetes or pre-diabetes or metabolic syndrome.

 

Could this study be right for you?

• Age ≥ 18 years old and ≤ 80 years old & willingness to be randomized to either diet.
• NYHA class I – III for at least 3 months.
• Ejection fraction ≥50% by biplane 2D, or 3D echo, or CMR.
• Echo findings of abnormal or indeterminant diastolic function or RHC data: At rest: mean pulmonary capillary wedge pressure (PCWP) > 15 mmHg. Pulmonary vascular resistance (PVR) < 3 Wood Units.
• Stable medical therapy for at least 3 months as determined by the treating physician (no new cardiac or diabetic medications within 3 months of enrollment or during enrollment and dosage should be stable for 1 month prior to enrollment).
• Dose of oral diuretics changes allowed but must be stable for 1 week prior to randomization.
• Body Mass Index (BMI) ≥ 25 and ≤ 50 or Type 2 Diabetes Mellitus or prediabetes (fasting glucose of 100 - 125 mg/dL or hemoglobin A1C 5.7-6.4%) or metabolic syndrome.
• Ability to participate in exercise treadmill testing.
• Ability to sign written consent.

Exclusions:

• Women who are pregnant, current breast-feeding, or have intention to become pregnant while in the study.
• Known allergy or sensitivity to gadolinium-based contrast agents.
• Implanted pacemaker, cardioverter defibrillator, Cardiac resynchronization therapy, left ventricular assist devices.
• Other metallic implants/aneurysm clips that are contraindicated in MRI.
• Claustrophobia
• History of severe kidney disease of eGFR < 30 ml/kg/1.73m2.

Exclusion Criteria varies, please contact Study Coordinator.

Age Range

18 - 80 years

Official Title PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr adults

Purpose

The purpose of PREVENTABLE is to learn if taking a statin could help older adults live well for longer by preventing dementia, disability, or heart disease. The duration of the study will last 5 years. 

Could this study be right for you?

Inclusion Criteria:

• Community-dwelling adults
• Age ≥75 years
• English or Spanish as primary language

 

Exclusion Criteria:

• Clinically evident cardiovascular disease defined as prior myocardial Infarction (MI), prior stroke, prior revascularization procedure, or a secondary prevention indication for a statin (clinician determined)
• Hospitalization for a primary diagnosis of heart failure in the prior 12 months (Note: History of heart failure in the absence of recent hospitalization or clinically evident cardiovascular disease is not an exclusion)
• Dementia (clinically evident or previously diagnosed)
• Dependence in any Katz Basic Activities of Daily Living [ADL] (with the exception of urinary or bowel continence)
• Severe hearing impairment (preventing phone follow up)
• Unable to talk (preventing phone follow up)

Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

75 years and up